ArticleArchives of pharmacal research2025
Constituents from Caragana jubata (Pall.) Poir. and their in vitro neuroprotective effects.
Article in Archives of pharmacal research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The present study aimed to isolate compounds from Caragana jubata (Pall.) Poir. and evaluate their in vitro neuroprotective effects. The compounds were isolated by various column chromatographic techniques and semipreparative HPLC. The structures of the new compounds were elucidated using HR‒ESI‒MS, UV, IR, 1D and 2D NMR, and single X-ray diffraction data analysis. Furthermore, their absolute configurations were determined through ECD spectroscopic data analysis. An oxygen‒glucose deprivation/reperfusion (OGD/R)-induced PC12 cell model and LPS-induced NO release from a BV2 cell model were established to evaluate their in vitro neuroprotective effects. Four undescribed compounds (1‒4), comprising one rare rearranged isoflavanone derivative with a 6/6/6/6 four-ring system, one isoflavanone, and two isoflavones, together with 21 known compounds, were isolated from C. jubata. The steric configurations of compound 5 were determined for the first time. Compounds 1‒5, 7‒9, 11‒12, 14‒15, and 17‒21 showed protective effects against OGD/R-induced PC12 cells in a range of 3.125 to 25 µM. (‒)-Caraflavonoid B (2b) displayed the most prominent protective activity. In addition, compound 2b had antineuroinflammatory activity. Results of network pharmacology indicate compound 2b may exert anti-ischemic stroke (anti-IS) effect by modulating multiple targets and pathways.
Indexed as
Identifiers
41326951What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.